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Summary
Objective: To compare the pharmacokinetics of glucosamine and the synovial ﬂuid levels attained following treatment with glucosamine
sulphate or glucosamine hydrochloride in a large animal model at clinically relevant doses.
Methods: Eight adult female horses were used. Crystalline glucosamine sulphate (Dona) or glucosamine hydrochloride was administered at
a dose of 20 mg/kg by either intravenous (IV) injection or nasogastric (NG) intubation. Plasma samples were collected before dosing and at 5,
15, 30, 60, 120, 360, 480 and 720 min after dosing. Synovial ﬂuid samples were collected from the radiocarpal joints within 48 h before dosing
and at 1, 6 and 12 h post-dosing. Glucosamine was assayed by Liquid Chromatography Electrospray Tandem Mass Spectrometry (LC-ESI/
MS/MS).
Results: Plasma concentrations reached w50 mg/mL after IV injection and w1 mg/mL after NG administration of both types of glucosamine.
The median oral bioavailability was 9.4% for glucosamine sulphate and 6.1% for glucosamine hydrochloride. Synovial ﬂuid concentrations
were signiﬁcantly higher at 1 and 6 h following oral treatment with glucosamine sulphate compared to glucosamine hydrochloride. Twelve
hours following oral administration, glucosamine levels in the plasma and the synovial ﬂuid were still signiﬁcantly higher than baseline for
the glucosamine sulphate preparation, but not for the hydrochloride preparation.
Conclusion: Following oral administration of a clinically recommended dose of glucosamine sulphate (Dona), signiﬁcantly higher synovial
ﬂuid concentrations of glucosamine are attained, when compared to an equivalent dose of glucosamine hydrochloride. Whether this difference
is translated into a therapeutic effect on the joint tissues remains to be elucidated.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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An ideal therapeutic agent for osteoarthritis (OA) would be
both disease and symptom-modifying and have minimum
side effects. Several investigations suggest that glucos-
amine therapy meets this ideal1e3, however, to the contrary,
a number of studies have not been able to detect any
beneﬁcial effects4e6. Consequently, glucosamine therapy
for OA remains a contentious issue. Results of two prospec-
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973demonstrated that oral glucosamine sulphate slowed the
radiographic progression of OA, supporting the concept
that it may be a disease-modifying OA drug2,3. Recently,
the oral administration of glucosamine hydrochloride was
shown to have a site-speciﬁc, but partial diseaseemodifying
effect in an experimental animal model of OA7. However, it
was emphasised in this study that the effects were modest,
as ulcerations of cartilage still occurred in some animals
receiving glucosamine7.
Despite multiple double-blind controlled clinical trials on
the use of glucosamine in OA, the controversy on its efﬁ-
cacy related to symptomatic improvement continues8,9.
The recently published Glucosamine/Chondroitin Arthritis In-
tervention Trial (GAIT) indicated that the symptomatic effect
of glucosamine hydrochloride at the dose of 500 mg three
times daily did not differ signiﬁcantly from placebo10. How-
ever, in a subgroup of patients with moderate-to-severe
knee pain, the rate of response to a combination of
500 mg glucosamine hydrochloride and 400 mg chondroitin
sulphate three times daily was signiﬁcantly higher than the
974 M. Meulyzer et al.: Pharmacokinetics of glucosamineresponse to placebo10. In contrast, the Glucosamine
Unum in Die Efﬁcacy (GUIDE) trial reported a signiﬁcant
improvement in the Lequesne algofunctional index when
glucosamine sulphate, at the dose of 1500 mg once-a-day,
was compared to placebo11. The discrepancies in outcome
of these two studies fuel the debate about the efﬁcacy of
glucosamine therapy in OA.
In Europe, a patented formulation of glucosamine
sulphate is a prescription drug, whereas in North America
glucosamine is considered to be a dietary supplement. A
crystalline glucosamine sulphate formulation (Dona,
Viartril-S, Xicil or other trademark) is patented by the Rot-
tapharm Group (Monza, Italy) with glucosamine, sulphate,
chloride and sodium ions present in stoichiometric ratios
of 2:1:2:2. Over-the-counter glucosamine formulations, on
the other hand, may contain glucosamine sulphate, glucos-
amine hydrochloride or N-acetylglucosamine and poor
product quality has been reported for a variety of these
formulations with only a small percentage of the products
actually containing the amount of product listed on the
label12,13.
Information on the absorption, serum pharmacokinetics
and synovial ﬂuid concentrations of glucosamine has
been limited until recently. In a large animal model Laverty
et al. demonstrated that glucosamine enters the synovial
ﬂuid following administration of recommended oral doses
of glucosamine hydrochloride14. The concentrations ob-
tained in the synovial ﬂuid were less than 10% of those in
serum, at the same time points14, suggesting that the
majority of the absorbed glucosamine is excreted or
metabolised by other tissues and therefore not available
for transportation from the circulation into the synovial ﬂuid.
Recently, synovial ﬂuid glucosamine concentrations have
been measured in human OA patients, following repeated
oral crystalline glucosamine sulphate administration at ther-
apeutic doses and the median synovial ﬂuid glucosamine
concentrations were only 23.5% lower than those in
plasma15.
In a Cochrane review it was speculated that the conﬂict-
ing trial results might be attributed to the use of different glu-
cosamine formulations, and it was concluded that the most
favourable trial results were associated with the prescription
glucosamine sulphate preparation16. Whether there is a dif-
ference in bioavailability and efﬁcacy between glucosamine
sulphate and glucosamine hydrochloride is presently
unknown. It has been proposed that eventual differences
in absorption could be explained by a different salt compo-
sition of the two formulations14.
The objectives of the present study were twofold: to
compare the pharmacokinetics of glucosamine following
treatment with glucosamine sulphate or glucosamine hydro-
chloride at clinically recommended doses and to compare
the synovial ﬂuid levels attained when each formulation
was administered.
MethodsMATERIALSGlucosamine sulphate (Dona) was purchased from Rotta Pharmaceuti-
cals Inc. (Wall, NJ, USA). Glucosamine hydrochloride (catalogue no. G1514,
purity 99%) and the internal standard (theophylline) were purchased from
SigmaeAldrich (St-Louis, MO, USA). Other chemicals, including acetonitrile
and formic acid were purchased from J.T. Baker (Phillipsburg, NJ, USA).ANIMAL STUDIESEight adult female horses, with a mean SD body weight of 459 42 kg
and a mean SD estimated age of 14.4 2.1 years were used in this study.These animals were free of clinical evidence of joint disease (absence of sy-
novial effusion in target joint and no lameness attributable to this joint). The
study was executed over a 4-week period. On week one, following a 12 h
fast, all horses were administered glucosamine sulphate by nasogastric
(NG) intubation which was followed 1 week later by intravenous (IV) admin-
istration of the same compound. On the third and fourth week the same pro-
tocol of administration was followed for glucosamine hydrochloride.
Crystalline glucosamine sulphate, a branded dietary supplement (Dona)
or analytical-grade glucosamine hydrochloride was dissolved at 100 mg/mL
in 0.9% sterile saline and adjusted to a pH of 6.0. The ﬁnal solution was ﬁl-
tered through a 0.2 mm ﬁlter and administered at a dose of 20 mg/kg body
weight by NG intubation or IV injection. Each horse received 20 mg glucos-
amine sulphate or glucosamine hydrochloride per kg bodyweight. NG dosing
included 500 ml of 0.9% sterile saline immediately after compound adminis-
tration. IV injection was via a catheter inserted into the right jugular vein and
was followed by a 20 mL saline ﬂush to assure complete drug administration.
Blood samples were collected into ethylenediaminetetraacetic acid
(EDTA) tubes via an IV catheter in the contralateral jugular vein and were ob-
tained within 48 h before dosing and at 5, 15, 30, 60, 120, 360, 480 and
720 min post-dosing. Synovial ﬂuid was collected in EDTA tubes by aseptic
arthrocentesis, within 48 h pre-dose from both radiocarpal joints and at 1, 6
and 12 h from only one radiocarpal joint. After NG administration, synovial
ﬂuid was obtained at 1 and 12 h post-dosing from the left and at 6 h post-dos-
ing from the right radiocarpal joint. The alternate sequence was used after IV
administration. Synovial ﬂuid and blood samples were centrifuged at 1000 g
for 20 min within 30 min of collection and the cell-free supernatants were re-
moved and stored at 80C until assayed for glucosamine.
Horses were evaluated daily for signs of discomfort or joint problems, for 2
days following the interventions and then every other day.
The experimental protocol was approved by the Institutional Animal Care
and Use Committee.QUANTIFICATION OF GLUCOSAMINE FROM PLASMA
AND SYNOVIAL FLUIDThe concentrations of glucosamine in the plasma and synovial ﬂuid
samples were assessed using Liquid Chromatography Electrospray Tandem
Mass Spectrometry (LC-ESI/MS/MS). Details of this method in equine plasma
have been reported elsewhere17. The reproducibility of the method was eval-
uated by analysing a minimum of six replicates of plasma and synovial ﬂuid
at the nominal glucosamine concentration of 20, 40 and 60 ng/mL with a cali-
bration curve made in saline solution (0.9% (w/v) NaCl in water) (Fig. 1). In
order to calculate the accuracy, the endogenous level needed to be subtracted
from the observed concentration of fortiﬁed equine plasma and synovial ﬂuid
(%NOM¼ ([measured concentration] [endogenous concentration])/[fortiﬁed
concentration]100). The precision (%CV) and accuracy (%NOM) observed
ranged from 5.3 to 11.3% and from 87.8 to 107.2% in equine plasma and
from 6.2 to 11.2% and from 85.5 to 113.1% in synovial ﬂuid. The interbatch pre-
cision observed ranged from 5.2 to 8.2%, whereas the accuracy ranged from
90.8 to 112.9%, respectively. Precision and accuracy in samples prepared in
saline solutionwere also calculated andwerewell within15%acceptance cri-
teria. The limit of quantiﬁcation (LOQ) was set at 10 ng/mL and, according to
the bioanalytical validation guideline published by the FDA in May 200118,
acceptable precision and accuracy results were achieved.PHARMACOKINETICSPharmacokinetic parameters of glucosamine in equine plasma were calcu-
lated using non-compartmentalmethods19. Theareaunder the curve from time
0e12 h (AUC0e12h) was calculated using a linear trapezoidal rule. A terminal
rate constant of elimination (kel) was calculated using aminimum of threemea-
surable plasma concentrations and the terminal elimination half-life (T1/2) was
calculated (T1/2¼ (ln 2)/kel). The area under the curve extrapolated to inﬁnity
(AUC0einf) was calculated using AUC0e12hþClast/kel, where Clast was the
last measurable plasma concentration.
After IV administration, the systemic clearance (CL) was calculated by di-
viding the actual dose administrated by the AUC0einf. The mean residence
time (MRT) was obtained by dividing the area under the ﬁrst momentetime
curve (AUMC0einf) by the AUC0einf. The total volume of distribution (Vd)
was calculated using CLMRT. After NG administration, the apparent clear-
ance (CL/F ) was calculated by dividing the dose by the AUC0einf. The
maximal serum concentration (Cmax) and the time to attain it (Tmax) were
also determined. The bioavailability (F ) of glucosamine sulphate and
glucosamine hydrochloride was calculated using the formula
(AUC0–inf NG/AUC0einf IV)  (DoseIV/DoseNG).STATISTICSFor each pharmacokinetic parameter, the median value in each treatment
group was compared using Wilcoxon Signed Rank Tests. Endogenous
Fig. 1. Quantiﬁcation of glucosamine by Liquid Chromatography Electrospray Tandem Mass Spectrometry (LC-ESI/MS/MS). (A) Chromato-
gram of a blank sample. (B) Chromatogram of an extracted horse plasma sample with endogenous glucosamine.
975Osteoarthritis and Cartilage Vol. 16, No. 9levels of glucosamine were examined using a repeated-measures linear
model with compartment (plasma or synovial ﬂuid) and type of glucosamine
(sulphate and hydrochloride) as repeated factors. A repeated-measures lin-
ear model, with time (1, 6 and 12 h) and type of glucosamine as repeated
factors, was used to investigate changes in synovial ﬂuid glucosamine con-
centrations following either IV or NG dosing. We used a priori contrasts to
examine differences between treatments at each time period. The actual
dose administered was normalised according to product potency (free glu-
cosamine) for statistical comparisons of the AUC of both formulations.Results
All procedures were well tolerated by the animals and no
adverse reactions were observed following the administra-
tion of both glucosamine formulations. One horse alone,
with a nervous temperament, was sedated prior to the
arthrocentesis procedures.QUANTIFICATION OF PLASMA GLUCOSAMINE FOLLOWING
IV DOSINGThe individual data of each animal were used to generate
the pharmacokinetic parameters of IV glucosamine sul-
phate and hydrochloride in plasma (Table I). Mean SD
plasma glucosamine concentrations at selected time pointsTable
Mean (SD) and median (range) pharmacokinetic parameters of glucosam
glucosamine sulphate or gluc
Glucosamine sulphate
Mean (SD) Median (ran
AUC0e12h, mg/h/L 56.08 (14.01) 53.71 (41.11e7
AUC0einf, mg/h/L 57.64 (14.42) 55.47 (41.47e7
T1/2, h 2.30 (0.40) 2.40 (1.70e2.
CL, L/h/kg 0.29 (0.07) 0.29 (0.20e0.
MRT, h 2.14 (0.53) 2.10 (1.48e3.
Vd, L/kg 0.61 (0.17) 0.60 (0.30e0.
AUC0e12h¼ area under the curve from time 0 to 12 h; AUC0einf¼ area
CL¼ systemic clearance; MRT¼mean residence time; Vd¼ total volumefollowing IV administration of glucosamine sulphate and
glucosamine hydrochloride are presented in Fig. 2. For
both types of glucosamine, the pharmacokinetic proﬁle
was characterised by a rapid decline over the ﬁrst 2 h after
IV administration, followed by a more progressive elimina-
tion in the following hours to reach a meanSD plasma
concentration of 433.3 245.1 ng/mL for glucosamine
sulphate and 305.0 136.4 ng/mL for glucosamine hydro-
chloride at 12 h post-treatment.
There was no signiﬁcant difference between the median
AUC0e12h or the median AUC0einf of both IV treatments.
The T1/2 for both treatments was variable between animals,
ranging from 1.7 h to 2.9 h for glucosamine sulphate and
from 1.7 h to 2.6 h for glucosamine hydrochloride, but the
variability was consistent with inter-animal variation in tis-
sue clearance. The median T1/2 was not signiﬁcantly differ-
ent between treatments, nor was the median CL, the
median MRT or the median Vd.QUANTIFICATION OF PLASMA GLUCOSAMINE FOLLOWING
NG DOSINGMeanSD plasma glucosamine concentrations at all
time points following NG administration of glucosamineI
ine in equine plasma (n¼ 8) following IV administration of 20 mg/kg
osamine hydrochloride
Glucosamine hydrochloride
ge) Mean (SD) Median (range)
7.10) 51.16 (12.66) 53.62 (34.45e66.99)
7.67) 52.28 (12.79) 55.41 (35.05e67.55)
90) 2.16 (0.35) 2.10 (1.68e2.60)
38) 0.34 (0.09) 0.30 (0.25e0.47)
10) 1.85 (0.34) 1.70 (1.43e2.37)
81) 0.62 (0.20) 0.66 (0.35e0.86)
under the curve extrapolated to inﬁnity; T1/2¼ elimination half-life;
of distribution.
Fig. 2. Mean (SD) plasma concentrations of glucosamine in horses (n¼ 8) following IV administration of 20 mg/kg glucosamine sulphate
(A) or glucosamine hydrochloride (B); following NG administration of 20 mg/kg glucosamine sulphate (C) or glucosamine hydrochloride (D).
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Fig. 2. At pre-dose, glucosamine plasma concentrations
ranged from <10 ng/mL (below LOQ) to 39.1 ng/mL. The
difference in endogenous plasma concentrations at base-
line between treatment groups was not statistically different.
Following NG administration both glucosamine formula-
tions were readily absorbed, reaching maximum plasma
concentrations 30 min to 2 h post-treatment. The
meanSD maximal plasma concentration was 1077.8
171.0 ng/mL for glucosamine sulphate compared to
935.7 267.8 ng/mL for glucosamine hydrochloride. The
difference in median maximal plasma concentrations be-
tween the two treatments was not statistically signiﬁcant.
The peak plasma concentrations were followed by
a progressive decline to meanSD plasma concentrations
of 131.0 52.1 ng/mL for glucosamine sulphate and
48.4 31.0 ng/mL for glucosamine hydrochloride at 12 h
post-dosing. At this time point, the plasma glucosamineTable I
Mean (SD) and median (range) pharmacokinetic parameters of gluc
20 mg/kg glucosamine sulphate o
Glucosamine sulphate
Mean (SD) Median (ra
AUC0e12h, mg/h/L 4.86 (1.42) 4.58* (3.29e
AUC0einf, mg/h/L 5.61 (1.69) 5.08* (3.91e
Cmax, mg/mL 1.08 (0.17) 1.13 (0.83e
Tmax, h 0.86 (0.52) 0.80 (0.50e
T1/2, h 3.90 (0.70) 4.00 (2.80e
CL/F, L/h/kg 2.99 (0.77) 3.09* (1.74e
Bioavailability, % 10.80 (5.60) 9.40 (5.20e
AUC0e12h¼ area under the curve from time 0 to 12 h; AUC0einf¼ area
concentration; Tmax¼ time to attainment of maximum plasma concentrati
*P 0.05.levels were not signiﬁcantly different from baseline levels
in the glucosamine hydrochloride group, in contrast with
the plasma concentrations 12 h post-treatment in the
glucosamine sulphate treatment group (P¼ 0.03).
The descriptive statistics for the pharmacokinetic param-
eters of both types of glucosamine in plasma after NG
dosing are presented in Table II. The median elimination
half-life of glucosamine sulphate and glucosamine hydro-
chloride after oral treatment was 4.0 h (range: 2.8e4.7)
and 3.0 h (range: 1.8e4.1), respectively (P¼ 0.055). The
median AUC0e12h and the median AUC0einf were higher
(P¼ 0.02 and P¼ 0.008) following NG administration of glu-
cosamine sulphate when compared to glucosamine hydro-
chloride. The median CL/F for glucosamine, on the
other hand, was lower after oral glucosamine sulphate treat-
ment compared to glucosamine hydrochloride treatment
(P¼ 0.008). When the bioavailabilities of both formulations
were compared, the median bioavailability was marginally,I
osamine in equine plasma (n¼ 8) following NG administration of
r glucosamine hydrochloride
Glucosamine hydrochloride
nge) Mean (SD) Median (range)
7.76) 3.23 (0.79) 3.36* (1.86e4.27)
9.01) 3.47 (0.86) 3.60* (2.01e4.59)
1.30) 0.94 (0.27) 0.90 (0.58e1.30)
2.00) 0.81 (0.26) 1.00 (0.50e1.00)
4.60) 2.88 (0.80) 3.00 (1.80e4.10)
4.01) 5.10 (1.54) 4.62* (3.61e8.27)
21.70) 6.90 (2.10) 6.10 (3.90e10.30)
under the curve extrapolated to inﬁnity; Cmax¼maximum plasma
on; T1/2¼ elimination half-life; CL/F¼ apparent clearance.
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mulation compared to the hydrocholoride salt (P¼ 0.08).
The median oral bioavailability of glucosamine sulphate
was 9.4 and 6.1% for glucosamine hydrochloride.QUANTIFICATION OF SYNOVIAL FLUID GLUCOSAMINE
FOLLOWING IV AND NG DOSINGEndogenous glucosamine concentrations in synovial ﬂuid
prior to NG glucosamine administration ranged from<10 ng/
mL (below LOQ) to 24.6 ng/mL. These values were not sig-
niﬁcantly different from endogenous plasma concentrations
and the measured levels of endogenous glucosamine were
not signiﬁcantly different between treatment groups.
FollowingNGadministrationmean SDmaximal synovial
ﬂuid glucosamine concentration was 153.6 32.9 ng/mL
with glucosamine sulphate administration and
92.7 34.9 ng/mL following glucosamine hydrochloride ad-
ministration (Table III). These values represent 14.3 and
9.9% of the mean maximal plasma concentrations achieved
in the same groups, respectively. Twelve hours post-dosing
meanSD synovial ﬂuid concentrations were lowered to
36.4 25.0 and 12.3 6.2 ng/mL, respectively. The differ-
ence in synovial ﬂuid concentrations attained following NG
administration of glucosamine sulphate and glucosamine hy-
drochloride was statistically signiﬁcant at 1 (P¼ 0.0004) and
6 h (P¼ 0.02), but not at 12 h (P¼ 0.07) post-treatment.
However, 12 h post-treatment, the glucosamine levels in
the synovial ﬂuid were still signiﬁcantly higher than baseline
levels following oral administration of glucosamine sulphate
(P¼ 0.03). In contrast, no signiﬁcant difference in glucos-
amine levels between baseline and 12 h post-treatment oc-
curred in the glucosamine hydrochloride group.
Following IV administration mean SD maximal synovial
ﬂuid concentrations were 1687.4 809.2 ng/mL for glucos-
amine sulphate and 1487.7 830.8 ng/mL for glucosamine
hydrochloride, respectively, 4.02 and 3.38% of the mean
maximal plasma concentrations. The difference in synovial
ﬂuid concentrations attained between treatment groups was
not statistically signiﬁcant following IV treatment.Discussion
The present study demonstrates that signiﬁcantly higher
synovial ﬂuid levels of glucosamine are attained following
the administration of the crystalline glucosamine sulphate
formulation (Dona) when compared to glucosamine hydro-
chloride at the same therapeutic dose. Interestingly, theTable I
Mean (SD) and median (range) glucosamine levels (ng/mL) in equine
glucosamine sulphate or gluc
Time (h) Glucosamine sulphate
Mean (SD) Median (range)
IV
1 1687.4 (809.2) 1493.9 (431.0e3169.0
6 517.9 (266.8) 469.3 (126.3e1023.4
12 500.7 (296.6) 409.2 (208.8e1153.0
NG
1 153.6 (32.9) 158.3* (104.9e199.5)
6 52.3 (17.3) 57.3* (21.4e69.9)
12 36.4 (25.0) 24.2 (16.1e84.1)
Blq¼ below LOQ (<10 ng/mL).
*P 0.05.differences were observed following NG but not IV adminis-
tration, indicating that absorption or metabolic factors may
account for this difference. This could be explained by
a higher absolute oral bioavailability of glucosamine with
the glucosamine sulphate formulation compared to the
hydrochloride salt. However, neither the difference in bio-
availability nor the difference in mean maximal plasma con-
centrations observed reached statistical signiﬁcance.
In the present study the median oral bioavailability of
glucosamine following administration of glucosamine sul-
phate and glucosamine hydrochloride was 9.4 and 6.1%,
respectively. Previous animal studies reported glucosamine
bioavailability following glucosamine hydrochloride adminis-
tration of 19% in rats20, 12% in dogs21 and 2e5% in
horses14,22. These differences could be due to inter-species
effects but also due to differences in study design and the
use of different formulations as well as analytical methods
in the various investigations. The absolute oral bioavailabil-
ity of glucosamine following glucosamine sulphate adminis-
tration in man has, in the past, been estimated to be 44%,
following radiolabelled glucosamine administration23. This
method does not allow differentiation between the
unchanged drug and its metabolites, and consequently
systemic availability may be overestimated20,21.
It is possible that glucosamine could exert its beneﬁcial
effects on either the synovial membrane or other peri-artic-
ular structures. Glucosamine hydrochloride at a clinically
relevant dose has been shown to partially inhibit the high
turnover of the subchondral bone in OA24 providing support
for peri-articular effects. The plasma levels, rather than
synovial levels, could therefore be more relevant to the de-
bate on its action. In this study oral glucosamine administra-
tion resulted in maximal plasma concentrations that were
higher following NG treatment with glucosamine sulphate
(mean Cmax¼ 1077.8 ng/ml or 6.2 mM) compared to glucos-
amine hydrochloride (mean Cmax¼ 935.7 ng/ml or 5.2 mM),
but, again, the difference was not statistically signiﬁcant.
Therefore the maximal plasma concentrations after oral
administration of both glucosamine formulations cannot ac-
count for the more favourable clinical trial results observed
with the prescription glucosamine sulphate formulation.
The AUC0e12h and AUC0einf were signiﬁcantly higher and
the clearance of glucosamine from the plasma was signiﬁ-
cantly lower following NG administration of glucosamine sul-
phate compared to oral treatment with glucosamine
hydrochloride, but there was no signiﬁcant difference after
IV administration. These data suggest that differences ob-
served are likely due to the different composition of both
formulations. The hydrochloride salt was administered asII
synovial fluid (n¼ 8) following IV or NG administration of 20 mg/kg
osamine hydrochloride
Glucosamine hydrochloride
Mean (SD) Median (range)
) 1487.7 (830.8) 1565.4 (299.5e2539.5)
) 505.2 (239.4) 521.7 (173.0e801.6)
) 480.2 (251.8) 398.5 (235.5e890.0)
92.7 (34.9) 88.9* (50.0e156.7)
19.9 (10.3) 14.4* (10.4e35.8)
12.3 (6.2) 10.5 (blqe20.7)
978 M. Meulyzer et al.: Pharmacokinetics of glucosaminea pure substance and would not be expected to markedly in-
ﬂuence the uptake or metabolism of glucosamine14. Glucos-
amine sulphate, on the other hand, was a commercially
available crystalline formulation (Dona) that contained other
substances such asNaþ, Cl, aspartame, citric acid, sorbitol,
polyethylene glycol 400 (PEG 400) and phenylalanine. Most
of these ingredients are used to improve the palatability of the
compounds. However, PEG 400 could potentially alter glu-
cosamine solubility and release, and consequently inﬂuence
its absorption, distribution and clearance19. Therefore, the
beneﬁcial effects attributed to glucosamine sulphate could
in some way be related to its formulation and to the length
of exposure to overall higher concentrations of glucosamine,
that are available for penetration into the joints resulting in
higher intra-synovial concentrations.
It is interesting to note that the mean maximal steady
state concentration (Css,max) reported in humans following
an equivalent, but repeated, dose of glucosamine sulphate
was 1601.9 ng/mL (8.9 mM)25 suggesting a higher bioavail-
ability of glucosamine sulphate in humans. In the latter
study plasma concentrations of glucosamine were still
above baseline levels 48 h post-dosing and pharmacokinet-
ics were at steady state after 3 consecutive days of once-a-
day oral treatment with crystalline glucosamine sulphate25.
The data in the study herein were generated following
a single dose administration of glucosamine products.
Based on the glucosamine half-life and elimination time of
our study a ‘‘steady state’’ situation is not feasible without
a dramatic increase in dosage or administration times.
The same conclusion was made by Biggee et al. in an
investigation in humans26, and also in an investigation in
dogs where no signiﬁcant differences were present be-
tween single and multiple dose pharmacokinetics following
oral administration of glucosamine hydrochloride21.
FollowingNGadministrationmean SDmaximal synovial
ﬂuid concentration was 153.6 32.9 ng/mL (0.86 mM) for
glucosamine sulphate and 92.7 34.9 ng/mL (0.52 mM) for
glucosamine hydrochloride and the difference in synovial
ﬂuid concentrations attained was statistically signiﬁcant for
up to 6 h post-treatment. However, the attained synovial ﬂuid
concentrations with both types of glucosamine were only
w10% of those obtained in plasma following NG dosing.
These values conﬁrm the data in our previous study on glu-
cosamine hydrochloride in the same large animal model14
but using different analytical methods ﬂuorophore-assisted
carbohydrate electrophoresis (FACE) and contrast with ﬁnd-
ings in a human study of glucosamine sulphate where syno-
vial ﬂuid concentrations were only approximately 25% lower
than plasma concentrations15. In the latter study 1500 mg
of crystalline glucosamine sulphate was administered orally,
once daily, for 14 consecutive days and plasma and synovial
ﬂuid concentrations were considered to be at steady state. In
the present study, on the other hand, the attained synovial
ﬂuid levels are the result of a single doseadministration of glu-
cosamine and clearance data indicate that a steady state
would be impossible to achieve with the same formulations
and dose regimens. Another possible explanation for the dis-
crepancy between the plasma/synovial ﬂuid concentration
ratio between equine and human studies is a species differ-
ence. In the present study we used an equine model that
has proven its suitability for pharmacokinetic studies of this
type14. This model is particularly useful because of the ability
to harvest large quantities of synovial ﬂuid without lavage in
normal animals. Persianiet al., on theother hand, studiedglu-
cosamine sulphate pharmacokinetics in human OA
patients15. While glucosamine is considered to be an ultraﬁl-
trate of plasma27, results from the latter study suggest thatglucosamine does not diffuse readily from the circulation
into the joint cavity. A species-speciﬁc difference in diffusion
would be difﬁcult to explain. The joints of the horses in the
present study were clinically normal. In OA joints the synovial
lining demonstrates non-speciﬁc changes of chronic, mild in-
ﬂammation28. Previous experimental animal studies have
demonstrated that the permeability of different substances
through the synovial membrane changes in response to in-
ﬂammation29,30. The observed difference in intra-articular
glucosamine diffusionmight therefore be explained as the re-
sult of inﬂammation of the synovium in OA joints. However, in
the above mentioned study, no information was supplied on
the inﬂammation status of the joints15. To the contrary, one
could also argue that moderate joint distension in response
to inﬂammation could have a dilutional effect on the mea-
sured glucosamine levels31. Further studies are warranted
to investigate the effect of joint inﬂammation on the concen-
trations of glucosamine attained in the synovial ﬂuid.
Most of glucosamine’s beneﬁcial effects were demon-
strated in the past by in vitro studies with concentrations
far exceeding those that can be obtained in plasma or syno-
vial ﬂuid after oral administration of recommended doses.
Recent investigations demonstrated that glucosamine may
also have beneﬁcial effects on articular cartilage explants
at biologically relevant doses32,33. However, the glucos-
amine concentrations employed in the latter experiments ap-
proximate the plasma concentrations that can be achieved
after NG dosing of glucosamine, but are higher than the con-
centrations we achieved in the synovial ﬂuid. Although the
treatment of horses with oral crystalline glucosamine
sulphate resulted in signiﬁcantly higher synovial ﬂuid
concentrations of glucosamine compared to glucosamine
hydrochloride, it remains questionable if the difference in
attained synovial ﬂuid concentrations, based on current
in vitro studies, explains the favourable results attained with
glucosamine sulphate administration in some clinical trials
in humans. The levels attained were very low and below
those observed to have in vitro effects on cartilage.
It could be argued that a limitation of the study design
was that an effect of time on glucosamine pharmacokinetics
could not be measured. However, no differences were
detected between baseline glucosamine levels measured
at the outset of the different arms of the study in the plasma
or synovial ﬂuid indicating that the design was robust for the
questions addressed. An additional limitation is that multiple
arthrocenteses at weekly intervals could alter the levels of
glucosamine measured in synovial ﬂuid by inducing inﬂam-
mation. In a previous study in horses from our laboratory34
the effect of repeated synoviocentesis on synovial inﬂam-
mation was assessed and no differences in inﬂammation
parameters were detected 1 week after synoviocentesis.
Another equine study indicated that the timing and duration
of the arthrocentesis effects on biomarkers of joint inﬂam-
mation varied per biomarker and the author recommended
waiting 1 week before repeating arthrocenteses when
studying markers of joint disease35. Combined, these stud-
ies suggest that repeated arthrocentesis at 1-week intervals
in this animal model does not alter inﬂammation parameters
and consequently should not alter kinetics (entry and clear-
ance) of the glucosamine in the joint.
In conclusion, following oral administration of crystalline
glucosamine sulphate (Dona) signiﬁcantly higher synovial
ﬂuid concentrations of glucosamine are attained when
compared to an equivalent dose of glucosamine hydrochlo-
ride. Whether this difference in synovial levels of glucos-
amine attained is translated into a therapeutic effect on
the joint tissues remains to be elucidated.
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